De Novo Mutations Affecting the Catalytic Cα Subunit of PP2A, PPP2CA, Cause Syndromic Intellectual Disability Resembling Other PP2A-Related Neurodevelopmental Disorders.


Journal

American journal of human genetics
ISSN: 1537-6605
Titre abrégé: Am J Hum Genet
Pays: United States
ID NLM: 0370475

Informations de publication

Date de publication:
03 01 2019
Historique:
received: 06 06 2018
accepted: 06 12 2018
pubmed: 1 1 2019
medline: 5 11 2019
entrez: 1 1 2019
Statut: ppublish

Résumé

Type 2A protein phosphatases (PP2As) are highly expressed in the brain and regulate neuronal signaling by catalyzing phospho-Ser/Thr dephosphorylations in diverse substrates. PP2A holoenzymes comprise catalytic C-, scaffolding A-, and regulatory B-type subunits, which determine substrate specificity and physiological function. Interestingly, de novo mutations in genes encoding A- and B-type subunits have recently been implicated in intellectual disability (ID) and developmental delay (DD). We now report 16 individuals with mild to profound ID and DD and a de novo mutation in PPP2CA, encoding the catalytic Cα subunit. Other frequently observed features were severe language delay (71%), hypotonia (69%), epilepsy (63%), and brain abnormalities such as ventriculomegaly and a small corpus callosum (67%). Behavioral problems, including autism spectrum disorders, were reported in 47% of individuals, and three individuals had a congenital heart defect. PPP2CA de novo mutations included a partial gene deletion, a frameshift, three nonsense mutations, a single amino acid duplication, a recurrent mutation, and eight non-recurrent missense mutations. Functional studies showed complete PP2A dysfunction in four individuals with seemingly milder ID, hinting at haploinsufficiency. Ten other individuals showed mutation-specific biochemical distortions, including poor expression, altered binding to the A subunit and specific B-type subunits, and impaired phosphatase activity and C-terminal methylation. Four were suspected to have a dominant-negative mechanism, which correlated with severe ID. Two missense variants affecting the same residue largely behaved as wild-type in our functional assays. Overall, we found that pathogenic PPP2CA variants impair PP2A-B56(δ) functionality, suggesting that PP2A-related neurodevelopmental disorders constitute functionally converging ID syndromes.

Identifiants

pubmed: 30595372
pii: S0002-9297(18)30453-1
doi: 10.1016/j.ajhg.2018.12.002
pmc: PMC6323609
pii:
doi:

Substances chimiques

Protein Subunits 0
PPP2CA protein, human EC 3.1.3.16
Protein Phosphatase 2 EC 3.1.3.16

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

139-156

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2018 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Références

J Biol Chem. 2012 Feb 10;287(7):4853-62
pubmed: 22167190
Nat Cell Biol. 2010 Sep;12(9):886-93
pubmed: 20711181
Mol Cell. 2016 Aug 18;63(4):686-695
pubmed: 27453045
Am J Physiol Heart Circ Physiol. 2000 Sep;279(3):H1307-18
pubmed: 10993798
Nat Commun. 2017 Dec 22;8(1):2272
pubmed: 29273778
Cell. 2006 Oct 20;127(2):341-53
pubmed: 17055435
Nature. 2014 Jul 17;511(7509):344-7
pubmed: 24896178
Nature. 2017 Feb 23;542(7642):433-438
pubmed: 28135719
Biochem J. 2001 Feb 1;353(Pt 3):417-39
pubmed: 11171037
J Clin Invest. 2015 Aug 3;125(8):3051-62
pubmed: 26168268
J Biol Chem. 1993 Sep 15;268(26):19192-5
pubmed: 8396127
Eur J Med Genet. 2010 Sep-Oct;53(5):239-43
pubmed: 20601260
Epilepsy Res. 2017 Mar;131:1-8
pubmed: 28199897
Nat Genet. 2001 Nov;29(3):287-94
pubmed: 11685209
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6043-7
pubmed: 8650216
FEBS J. 2013 Jan;280(2):644-61
pubmed: 22443683
Hum Mol Genet. 2015 Sep 1;24(17):4775-9
pubmed: 25972378
Trends Biochem Sci. 2008 Mar;33(3):113-21
pubmed: 18291659
Mol Cell. 2011 Feb 4;41(3):331-42
pubmed: 21292165
Nat Rev Genet. 2016 Jan;17(1):9-18
pubmed: 26503795
Biochem Biophys Res Commun. 2017 Dec 16;494(3-4):491-498
pubmed: 29066346
J Biol Chem. 1999 May 14;274(20):14382-91
pubmed: 10318862
Am J Hum Genet. 2016 Jan 7;98(1):58-74
pubmed: 26749308
Nature. 2015 Mar 12;519(7542):223-8
pubmed: 25533962
J Biol Chem. 1999 Aug 20;274(34):24038-46
pubmed: 10446173
N Engl J Med. 2012 Nov 15;367(20):1921-9
pubmed: 23033978
Am J Med Genet A. 2008 May 15;146A(10):1267-79
pubmed: 18412109
Nat Commun. 2013;4:2677
pubmed: 24157919
Nat Methods. 2014 Apr;11(4):361-2
pubmed: 24681721
Mol Cell Biol. 2011 Sep;31(18):3832-44
pubmed: 21791616
Hum Mutat. 2015 Oct;36(10):928-30
pubmed: 26220891
Cell Res. 2014 Feb;24(2):190-203
pubmed: 24100351
PLoS Genet. 2016 May 11;12(5):e1006022
pubmed: 27166630
Biochemistry. 1999 Dec 14;38(50):16539-47
pubmed: 10600115
Cancer Res. 2016 Oct 1;76(19):5719-5731
pubmed: 27485451
Neurogenetics. 2016 Jan;17(1):43-9
pubmed: 26576547
Dev Dyn. 2014 Jun;243(6):778-90
pubmed: 24425002
Nat Neurosci. 2016 Sep;19(9):1194-6
pubmed: 27479843
Nat Commun. 2013;4:1699
pubmed: 23591866
Cancer Res. 2017 Dec 15;77(24):6825-6837
pubmed: 29046336
J Cell Biol. 2016 Aug 29;214(5):539-54
pubmed: 27551054
Biol Chem. 2014 Jul;395(7-8):881-9
pubmed: 25003389
Am J Med Genet A. 2003 Nov 15;123A(1):37-44
pubmed: 14556245
Lancet. 2012 Nov 10;380(9854):1674-82
pubmed: 23020937
Methods Mol Biol. 2013;1053:283-305
pubmed: 23860660
J Biol Chem. 2007 Sep 14;282(37):26971-80
pubmed: 17635907
Int J Biochem Cell Biol. 2018 Feb;95:53-62
pubmed: 29274472
Cancer Res. 2005 Sep 15;65(18):8183-92
pubmed: 16166293
Biochim Biophys Acta Mol Cell Res. 2019 Jan;1866(1):31-50
pubmed: 30030003

Auteurs

Sara Reynhout (S)

Laboratory of Protein Phosphorylation & Proteomics, Department of Cellular & Molecular Medicine, University of Leuven (KU Leuven), 3000 Leuven, Belgium; Leuven Brain Institute, PO Box 901, 3000 Leuven, Belgium.

Sandra Jansen (S)

Department of Human Genetics, Donders Institute for Brain, Cognition, and Behaviour, Radboudumc, PO Box 9101, 6500 HB Nijmegen, the Netherlands.

Dorien Haesen (D)

Laboratory of Protein Phosphorylation & Proteomics, Department of Cellular & Molecular Medicine, University of Leuven (KU Leuven), 3000 Leuven, Belgium; Leuven Brain Institute, PO Box 901, 3000 Leuven, Belgium.

Siska van Belle (S)

Laboratory of Protein Phosphorylation & Proteomics, Department of Cellular & Molecular Medicine, University of Leuven (KU Leuven), 3000 Leuven, Belgium; Leuven Brain Institute, PO Box 901, 3000 Leuven, Belgium.

Sonja A de Munnik (SA)

Department of Human Genetics, Donders Institute for Brain, Cognition, and Behaviour, Radboudumc, PO Box 9101, 6500 HB Nijmegen, the Netherlands.

Ernie M H F Bongers (EMHF)

Department of Human Genetics, Radboudumc, PO Box 9101, 6500 HB Nijmegen, the Netherlands.

Jolanda H Schieving (JH)

Department of Neurology, Radboudumc, PO Box 9101, 6500 HB Nijmegen, the Netherlands.

Carlo Marcelis (C)

Department of Human Genetics, Radboudumc, PO Box 9101, 6500 HB Nijmegen, the Netherlands.

Jeanne Amiel (J)

Laboratory of Embryology and Genetics of Human Malformations, Paris Descartes University, Sorbonne Paris Cité University and INSERM U1163, Institut Imagine, 75015 Paris, France; Service de Génétique, Hôpital Necker - Enfants Malades, Assistance Publique - Hôpitaux de Paris, 75015 Paris, France.

Marlène Rio (M)

Service de Génétique, Hôpital Necker - Enfants Malades, Assistance Publique - Hôpitaux de Paris, 75015 Paris, France.

Heather Mclaughlin (H)

GeneDx, 207 Perry Parkway, Gaithersburg, MD 20877, USA.

Roger Ladda (R)

Penn State Hershey Children's Hospital, Hershey, PA 17033, USA.

Susan Sell (S)

Penn State Hershey Children's Hospital, Hershey, PA 17033, USA.

Marjolein Kriek (M)

Department of Clinical Genetics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands.

Cacha M P C D Peeters-Scholte (CMPCD)

Department of Neurology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands.

Paulien A Terhal (PA)

Department of Genetics, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, the Netherlands.

Koen L van Gassen (KL)

Department of Genetics, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, the Netherlands.

Nienke Verbeek (N)

Department of Genetics, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, the Netherlands.

Sonja Henry (S)

Biochemical Genetics Clinic, University of Wisconsin School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705, USA.

Jessica Scott Schwoerer (J)

Biochemical Genetics Clinic, University of Wisconsin School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705, USA.

Saleem Malik (S)

Comprehensive Epilepsy Program, Jane and John Justin Neuroscience Center, Cook Children's Medical Center, Fort Worth, TX 76104, USA.

Nicole Revencu (N)

Centre de Génétique Humaine, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Avenue Hippocrate 10-1200, Brussels, Belgium.

Carlos R Ferreira (CR)

Office of the Clinical Director, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Ellen Macnamara (E)

Office of the Clinical Director, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA; NIH Undiagnosed Diseases Program, Common Fund, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Hilde M H Braakman (HMH)

Department of Neurology, Academic Center for Epileptology, Kempenhaeghe & Maastricht UMC+, Sterkelseweg 65, 5591 VE Heeze, the Netherlands.

Elise Brimble (E)

Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA.

Maura R Z Ruzhnikov (MRZ)

Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA; Department of Pediatrics, Division of Medical Genetics, Stanford Medicine, Stanford, CA 94305, USA.

Matias Wagner (M)

Institute of Human Genetics, Helmholtz Zentrum München, 85764 Munich, Germany; Institute of Human Genetics, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany; Institute of Neurogenomics, Helmholtz Zentrum München, 85764 Munich, Germany.

Philip Harrer (P)

Institute of Neurogenomics, Helmholtz Zentrum München, 85764 Munich, Germany.

Dagmar Wieczorek (D)

Institute of Human Genetics, Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany; Institut für Humangenetik, Universitätsklinikum Essen, Universität Duisburg-Essen, 45147 Essen, Germany.

Alma Kuechler (A)

Institut für Humangenetik, Universitätsklinikum Essen, Universität Duisburg-Essen, 45147 Essen, Germany.

Barak Tziperman (B)

Pediatric Neurology Unit, Sheba Medical Center, 52621 Ramat Gan, Israel.

Ortal Barel (O)

Genomic Unit, Sheba Cancer Research Center, Sheba Medical Center, 52621 Tel Hashomer, Israel; Wohl Institute for Translational Medicine, Sheba Medical Center, 52621 Tel Hashomer, Israel.

Bert B A de Vries (BBA)

Department of Human Genetics, Donders Institute for Brain, Cognition, and Behaviour, Radboudumc, PO Box 9101, 6500 HB Nijmegen, the Netherlands.

Christopher T Gordon (CT)

Laboratory of Embryology and Genetics of Human Malformations, Paris Descartes University, Sorbonne Paris Cité University and INSERM U1163, Institut Imagine, 75015 Paris, France.

Veerle Janssens (V)

Laboratory of Protein Phosphorylation & Proteomics, Department of Cellular & Molecular Medicine, University of Leuven (KU Leuven), 3000 Leuven, Belgium; Leuven Brain Institute, PO Box 901, 3000 Leuven, Belgium. Electronic address: veerle.janssens@kuleuven.be.

Lisenka E L M Vissers (LELM)

Department of Human Genetics, Donders Institute for Brain, Cognition, and Behaviour, Radboudumc, PO Box 9101, 6500 HB Nijmegen, the Netherlands. Electronic address: lisenka.vissers@radboudumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH